Key result
Nisoldipine lowers blood pressure in hypertensive patients without altering pharmacokinetics or causing drug accumulation.
Why the study?
Does long-term nisoldipine treatment alter its pharmacokinetics or hemodynamic effects in patients with essential hypertension?
Does long-term nisoldipine treatment alter its pharmacokinetics or hemodynamic effects in patients with essential hypertension?
Long-term treatment with nisoldipine in hypertensive patients effectively lowers blood pressure without altering its own pharmacokinetics or causing drug accumulation.
Answers are grounded in this paper and cite their sources.
May support chronic nisoldipine dosing in hypertension without accumulation; hypothesis-generating and requires larger randomized confirmation.
Summary: In six patients with essential hypertension, the pharmacokinetics of nisoldipine were investigated before, during, and after 4 weeks of treatment. On day 1, nisoldipine was infused intravenously (i.v. 2 mg in 2 h); on day 2, oral nisoldipine treatment (10-mg tablets twice daily) was started for 4 weeks. During this period, patients came to the hospital six times, on which occasions blood samples were taken for the determination of trough and peak concentrations of nisoldipine. After 4-week treatment, the infusion experiment was repeated. In the first infusion experiment, systemic clearance was 1.02 ± 0.23 L/min (mean ± SD), terminal half-life (t1/2) was 15.4 ± 6.7 h, and volume of distribution was 5.9 ± 1.8 L/kg. After 4 weeks, these parameters had not changed significantly. Nisoldipine lowered blood pressure (BP) in all patients, whereas forearm blood flow and heart rate (HR) increased. Neither were the hemodynamic changes different after the oral treatment period, although basal BP was lower than before oral treatment. No accumulation of nisoldipine occurred during the 4-weeks treatment period.
No takes yet. Share an insight, caveat, or question.
Harten et al. (1989) studied essential hypertension (n=6). Nisoldipine vs. Baseline (before treatment) was evaluated on Pharmacokinetics (systemic clearance, terminal half-life, volume of distribution) and hemodynamic effects. Nisoldipine treatment for 4 weeks in hypertensive patients lowered blood pressure without significant changes in pharmacokinetic parameters (clearance, half-life, volume of distribution) or accumulation.
Synapse has enriched 10 related papers. Consider them for comparative context: